Avicanna (OTCQX:AVCNF), a biopharmaceutical company focused on cannabinoid-based products, released its Q2 2022 highlights:
6-month revenue of $2.14 million, representing 101% increase from the same period in the prior year, supported by increased international and licensing revenue and through further progress across the Canadian commercialization efforts.
